Schrodinger Inc (SDGR) Reports Q1 2026 Results and Provides Full-Year Outlook
Schrodinger Inc reported a 12% YoY increase in annual contract value to $28.4 million for Q1 2026, driven by new deployments and usage scale-ups. The company anticipates full-year ACV growth of 10-15%, with drug discovery revenue expected between $55 million and $65 million.